Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years
Shameem Mahmood(The Royal Free Hospital), Ashutosh Wechalekar(University College Hospital), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Philip N. Hawkins(The Royal Free Hospital), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Carol Whelan(The Royal Free Hospital), Sajitha Sachchithanantham(The Royal Free Hospital), Lisa Rannigan(University College London), Frank Bridoux(Université de Poitiers), Ketna Patel(National Institutes of Health), Thirusha Lane(Boston University), Darren Foard(University College London), Rabya Sayed(National Institutes of Health), Marianna Fontanna(University College London)
Cited by 14
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k